Victor Vaughn, Supernus Pharmaceuticals, Inc. (SUPN)’s insider Unloaded 15,000 Shares; SYMMETRY TECH COMMON (SMMR) Shorts Increased By 150%

Victor Vaughn, the insider, who’s for the time being the Sr. VP of Sales of Supernus Pharmaceuticals Inc sold around 15,000 shares of the corporation with market value of roughly $630,650 U.S. Dollars based on a market stock price of 42.0 U.S. Dollars per share. In the last month, he also sold 55,000 shares worth total $2,206,309 USD. Currently, Mr. Victor, possess 9,344 shares, which accounts for 0.02% of the Company’s market cap. The insider’s activity definitely generated quite an interest in the stock community. This stock sale by Mr. Victor – was recorded on January 09, 2018 and disclosed in a SEC’s filing available here.

SYMMETRY TECH COMMON (OTCMKTS:SMMR) had an increase of 150% in short interest. SMMR’s SI was 500 shares in January as released by FINRA. Its up 150% from 200 shares previously. It closed at $0.03 lastly. It is down 0.00% since January 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on February, 27. They expect $0.26 earnings per share, 0.00% or $0.00 from last year’s $0.26 per share. SUPN’s profit will be $13.33 million for 41.06 P/E if the $0.26 EPS becomes a reality. After $0.29 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.34% negative EPS growth.

Among 10 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Supernus Pharmaceuticals has $53.0 highest and $27 lowest target. $45.80’s average target is 7.26% above currents $42.7 stock price. Supernus Pharmaceuticals had 35 analyst reports since August 26, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, September 27 by Cantor Fitzgerald. The firm has “Buy” rating by Jefferies given on Thursday, August 4. The firm has “Hold” rating by Zacks given on Wednesday, August 26. The firm has “Buy” rating given on Monday, November 20 by FBR Capital. The rating was maintained by Cantor Fitzgerald on Monday, September 18 with “Buy”. As per Wednesday, July 5, the company rating was maintained by Cantor Fitzgerald. The stock has “Overweight” rating by PiperJaffray on Thursday, June 1. The rating was maintained by Northland Capital on Thursday, November 5 with “Outperform”. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Thursday, August 3 by Cowen & Co. The firm has “Hold” rating given on Thursday, August 3 by Piper Jaffray.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $2.19 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 38.85 P/E ratio. The company??s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.34, from 1.32 in 2017Q2. It is negative, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Smith Asset Mgmt Grp L P has 61,367 shares. 8,588 are owned by Lenox Wealth Mngmt. Globeflex Capital L P stated it has 19,061 shares. Columbus Circle Invsts reported 12,035 shares. Goldman Sachs Group Incorporated Inc reported 301,323 shares stake. Moreover, Polar Cap Limited Liability Partnership has 0.15% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 338,956 shares. Royal Commercial Bank Of Canada holds 0% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 26,146 shares. New York-based Cornerstone Cap Holding Ltd Com has invested 0.03% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Hodges Capital Mngmt Inc invested in 0.89% or 328,945 shares. Regions Fincl Corp owns 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 12,490 shares. Riverhead Cap Mgmt Limited Company holds 0.01% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 3,586 shares. Group Incorporated Inc has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). State Street invested in 1.41 million shares. Scout Invests owns 565,900 shares or 0.62% of their US portfolio. Granite Prns Lc invested in 0.92% or 371,154 shares.

The stock increased 4.27% or $1.75 during the last trading session, reaching $42.7. About 744,574 shares traded or 62.97% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since January 10, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

Since August 16, 2017, it had 0 buys, and 5 insider sales for $9.43 million activity. Shares for $4.43M were sold by Schwabe Stefan K.F. on Thursday, September 7. PATRICK GREGORY S sold $2.38 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Thursday, September 7. $167,755 worth of stock was sold by Bhatt Padmanabh P. on Wednesday, August 16. Vaughn Victor sold 55,000 shares worth $2.21 million.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: